Press Release
Changes of Representative Directors and DirectorsTokyo, April 27, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "the Company" ) today announced that at a meeting of its Board of Directors held today, it decided changes of Representative Directors and Directors as stated below. These changes are subject to approval at the Ordinary General Meeting of Shareholders to be held on June 19, 2017 and decision at the Board of Directors meeting scheduled for the same day.
-
Changes of Representative Directors (New Representative Director candidate)
Kenji Yasukawa
(New) Representative Director, Executive Vice President
(Current) Senior Corporate Executive, Senior Vice President, CSTO & CCO
CSTO: Chief Strategy Officer CCO: Chief Commercial Officer
(Representative Director to be retired)Yoshirou Miyokawa
(Current) Representative Director, Executive Vice President
Effective date of changes: June 19, 2017
Reason for changes: Those changes are decided in order to pursue Astellas' growth strategies more vigorously by new leader.
1
- Curriculum Vitae of new Representative Director candidate
Name: Kenji Yasukawa Date of Birth: June 7, 1960 Place of Birth: Tokyo
-EducationMarch 1986 University of Tokyo, Master of Science, Agriculture July 2001 Showa University Graduate School of Pharmaceutical
Sciences, Japan, Ph.D. in Pharmaceutical Sciences
-Carrier HistoryApril 1986 Joined the Company (former Yamanouchi Pharmaceutical Co., Ltd.)
April 2005 Vice President, Project Management, Urology, the Company June 2010 Corporate Executive of the Company, Therapeutic Area Head,
Urology, Astellas Pharma Europe B.V.
October 2010 Corporate Executive of the Company, Therapeutic Area Head, Urology, Astellas Pharma Global Development, Inc.
April 2011 Corporate Executive, Vice President,
Product & Portfolio Strategy, the Company
April 2012 Corporate Executive, Senior Vice President and Chief Strategy Officer, the Company
June 2012 Senior Corporate Executive, Senior Vice President and Chief Strategy Officer, the Company
April 2017 Senior Corporate Executive, Senior Vice President, Chief Strategy Officer and Chief Commercial Officer, the Company
Ownership of shares: 11,315 shares (as of March 31, 2017)
-
New Candidates of Directors
Director Kenji Yasukawa
Outside Director Mamoru Sekiyama
Outside Director Keiko Yamagami
- Directors to be retired
Director Yoshirou Miyokawa
Outside Director Yutaka Kase
Outside Director Hironobu Yasuda
(Reference)
Curriculum Vitae of new Director candidates Name: Mamoru Sekiyama
Date of Birth: August 14, 1949
-Carrier History
April 1974 Joined Marubeni Corporation
April 1997 General Manager, Power Project Dept.-I, Marubeni Corporation April 1998 General Manager, Power Project Dept.-III, Marubeni Corporation April 1999 Deputy General Manager, Power Project Div.; General Manager,
Power Project Dept. I, Marubeni Corporation
April 2001 Senior Operating Officer, Utility Infrastructure Div.; General Manager, Overseas Power Project Dept., Marubeni Corporation
April 2002 Corporate Vice President, Chief Operating Officer, Plant, Power & Infrastructure Div., Marubeni Corporation
April 2005 Corporate Senior Vice President, Chief Operating Officer, Plant, Power & Infrastructure Projects Div., Marubeni Corporation
June 2006 Corporate Senior Vice President, Member of the Board, Marubeni Corporation
April 2007 Corporate Executive Vice President, Member of the Board, Marubeni Corporation
April 2009 Senior Executive Vice President, Member of the Board, Marubeni Corporation
April 2013 Vice Chairman, Marubeni Corporation
April 2015 Corporate Adviser, Marubeni Corporation (present post) Chairman, Marubeni Power Systems Corporation
Astellas Pharma Inc. published this content on 27 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 April 2017 03:07:11 UTC.
Original documenthttps://www.astellas.com/en/corporate/news/pdf/170427_Eg_3-2.pdf
Public permalinkhttp://www.publicnow.com/view/E88E4680DE908DC92F48E9B85440A54CB8F596C5